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Abstract
Suicide and nonfatal suicidal behaviors are major causes of mortality and morbidity worldwide. 
Variability in rates of suicide and suicidal behaviors within and between countries has been 
attributed to population and individual risk factors, including economic status and cultural 
differences, both of which can have suicide risk effects mediated through a variety of factors, of 
which perhaps the least understood is the role of diet. We therefore review the scientific literature 
concerning two major dietary lipid classes, cholesterol and polyunsaturated fatty acids (PUFAs), 
that have been associated with higher risk of suicide attempts and suicide. We consider potential 
mechanistic intermediates including serotonin transporters and receptors, toll-like receptors 
(TLRs), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), and peroxisome 
proliferator activated receptors (PPARs). Based on this review, we describe a theoretical model 
linking cholesterol and PUFA status to suicide risk, taking into account the effects of cholesterol-
lowering interventions on PUFA balance, membrane lipid microdomains (rafts) as a nexus of 
interaction between cholesterol and omega-3 PUFAs, and downstream effects on serotonergic 
neurotransmission and specific inflammatory pathways.
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1. Introduction
1.1. Lipids and suicide
Suicide and suicidal behaviors are among the leading causes of death and injuries 
worldwide. Approximately 800,000 people die from suicide each year, and suicide is the 
second leading cause of death in the 15-29 year-old cohort. Ten to twenty times more 
individuals attempt suicide, indicating that both suicide and non-fatal suicidal behaviors are 
prevalent and need to be addressed. (World Health Organization, 2014)
To understand the causes of suicide, prevalent explanatory models have focused on 
psychological factors such as feelings of thwarted belongingness, perceived 
burdensomeness, and hopelessness (Van Orden et al., 2010); neurobiological factors such as 
genetic risk, serotonergic functioning, and altered stress responses (Mann et al., 1999, 
Oquendo et al., 2014); and cultural factors (Chu et al., 2018).
Rates of suicide and suicidal behaviors vary geographically, with higher rates of suicide 
occurring in lower per capita-income regions (World Health Organization, 2017). Some 
portion of this variability may be attributable to economic and cultural differences that 
influence nutrition and in this way can impact the diathesis or predisposition to suicide 
behavior. One nutritional factor proposed to impact suicide and suicidal behavior is dietary 
lipid intake, presumably through lipid effects on brain. Two major lipid classes have been 
implicated in suicide risk, cholesterol and polyunsaturated fatty acids (PUFAs). We here 
review the evidence associating low cholesterol and low n-3 relative to n-6 PUFAs with 
suicide and suicidal behaviors. Finally, we present a neurobiological model proposing that 
the actions and interactions of cholesterol and PUFA status may influence suicide risk 
through effects on decreased serotonergic neurotransmission and/or increased inflammation 
(see Figure 1).
1.2. Low cholesterol and suicide risk
Cholesterol and cholesterol metabolites are abundant in the brain. Accounting for 2% of 
body weight, the brain has 25% of total body cholesterol (Dietschy and Turley, 2001). 
Cholesterol is essential for cell membrane stability and neurotransmission (Ghaemi et al., 
2000). An association between cholesterol and suicide was first reported in a 1990 meta-
analysis of primary intervention trials in cardiovascular illness, which found that cholesterol 
lowering treatments led to an excess in non-illness mortality, mostly suicide and injury 
(Muldoon et al., 1990). A second meta-analysis was carried out by the same group 11 years 
later, after hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, 
became the most commonly used cholesterol-lowering drug class. The authors concluded 
that overall, cholesterol-lowering treatments were not related to non-illness mortality, and 
that statins showed a tendency to reduce non-illness mortality (Muldoon, 2001). Non-statin 
treatments, however, including diet, did exhibit a trend (p=0.06) toward increased mortality 
from suicide, accidents and trauma (Muldoon et al., 2001).
In parallel, observational studies of cholesterol status in psychiatric populations have been 
summarized recently in a meta-analysis of 65 epidemiological studies, involving 510,392 
participants, studying associations between serum lipid levels and ‘suicidality’ (Wu et al., 
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2016). Included were studies that assessed total serum cholesterol (TC), high-density 
lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and/or 
triacylglycerols (TAG). The outcome measure of ‘suicidality’ was defined as including 
suicidal ideation, suicide attempt, having threatened suicide, or death by suicide. The main 
results were that TC and LDL-C levels were lower in suicidal patients than in non-suicidal 
patients and healthy controls; HDL-C levels were lower in suicidal patients than in healthy 
controls; and TG levels were lower in suicidal than in non-suicidal patients. When all three 
groups were pooled, lower serum TC was associated with higher risk of suicidality, suicide 
attempts, and suicide.
1.3. Low dietary intake of polyunsaturated fatty acids and suicide risk
Another lipid class implicated in suicide risk is polyunsaturated fatty acids (PUFAs), and it 
has been suggested that PUFA status may be an important factor in cholesterol associations 
with suicide risk (Hibbeln and Salem, 1996), as has also has been postulated for 
cardiovascular risk (de Lorgeril et al., 2005). Comprised of long carbon chains with two or 
more double bonds and categorized as n-3 or n-6 based on the number of carbon atoms from 
the terminal methyl (omega) end to the first double bond of the carbon chain, PUFAs are 
found in every cell of the human body and present in multiple lipid classes: esterified to 
triacylglycerol, cholesterol (as cholesteryl esters) and phospholipids, as well as existing as 
non-esterified (‘free’) fatty acids (reviewed in (Jump, 2002)). Both n-3 and n-6 PUFAs are 
defined as essential because humans and most other mammals cannot synthesize these 
compounds de novo (Spector, 1999), although ingested shorter-chain fatty acids, alpha 
linolenic acid (ALA, 18:3n-3) and linoleic acid (LA, 18:2n-6) can be converted to long-
chain PUFAs in the liver through a series of elongation and desaturation reactions. In the 
modern diet, whereas n-6 PUFAs are abundant in many plant-based oils and in meat from 
animals fed corn-based diets, the major source of n-3 PUFAs is seafood (Meyer et al., 2003, 
Simopoulos, 2011).
Several studies have linked PUFAs with suicide risk. A case-control study of emergency 
room patients showed that red blood cell levels of eicosapentaenoic acid (EPA, 20:5n-3) 
were lower in suicide attempters in comparison with controls (Huan et al., 2004). In a pilot 
study, low docosahexaenoic acid (DHA, 22:6n-3) percentages of total phospholipid fatty 
acids and elevated n-6 to n-3 ratios predicted suicidal behavior in patients with major 
depression (Sublette et al., 2006). Finally, a large (n=1600) retrospective case-control study 
of active duty US military personnel determined that low n-3 PUFA levels were associated 
with increased risk of suicide compared with other causes of death (Lewis et al., 2011). 
Higher blood levels of n-6 PUFAs also have been reported in association with higher suicide 
risk and depression in a study of 234 pregnant women (Vaz et al., 2014).
Lower n-3 PUFA levels are also observed in depressed patients compared with healthy 
controls, in plasma (Dinan et al., 2009, Féart et al., 2008, Frasure-Smith et al., 2004, Rees et 
al., 2009, Tiemeier et al., 2003) and serum (Conklin et al., 2007, Maes et al., 1999, Riemer 
et al., 2010, Schins et al., 2007) phospholipids, red blood cell membranes (Adams et al., 
1996, Amin et al., 2008, Edwards et al., 1998, McNamara et al., 2010b, Peet et al., 1998), 
and adipose tissue (Mamalakis, 2002, Mamalakis et al., 2006a, Mamalakis et al., 2006b, 
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Papandreou et al., 2011, Sarri et al., 2008), and confirmed by meta-analytic findings (Lin et 
al., 2010). These relationships are relevant since depression is one of the main risk factors 
associated with suicidal behavior (Teti et al., 2014).
Another suicide risk factor, the presence of impulsive/aggressive traits (van Heeringen and 
Mann, 2014), also has been observed to associate with lower n-3 PUFAs. In patients with 
deliberate self-harm, correlations were seen between low plasma levels of n-3 PUFAs and 
higher impulsivity scores (Garland et al., 2007). In context of substance use disorders, 
another risk factor for suicide (Tondo et al., 1999), low plasma EPA, was associated with 
aggression and impulsivity in adults with MDD and comorbid substance use disorders (Beier 
et al., 2014); and lower plasma levels of docosapentaenoic acid (DPA, 22:5n-6), DHA, and 
total n-3 PUFAs were found in aggressive cocaine addicts (Buydens-Branchey et al., 2003). 
Of note, a low cholesterol diet in nonhuman primates also is associated with serotonin 
neurotransmitter system deficits and greater aggressive behavior (Kaplan et al., 1994).
Meta-analyses provide variable conclusions concerning the therapeutic benefits of n-3 
PUFAs in depression (Appleton et al., 2006, Appleton et al., 2010, Appleton et al., 2015, 
Bloch and Hannestad, 2012, Grosso et al., 2014, Martins, 2009, Martins et al., 2012, 
Mocking et al., 2016, Sublette et al., 2011, Yang et al., 2015); disparities appear to stem 
from differences with regard to depression severity, selection of outcome measures, 
composition of n-3 PUFA supplements, and estimates of negative publication bias. There is 
considerable support for the finding that n-3 PUFA supplements have greatest efficacy in 
patients who have a diagnosis of major depression and when the n-3 supplement contains a 
greater proportion of EPA compared to DHA (Appleton, 2010, Grosso, 2014, Martins, 2009, 
Martins, 2012, Sublette, 2011, Yang, 2015).
Given that both cholesterol and PUFAs have been implicated in suicide risk, Hibbeln & 
Salem (Hibbeln and Salem, 1995, 1996) have suggested that PUFA status might be a 
confounder in the putative relationship between plasma cholesterol and suicide, citing 
effects of cholesterol-lowering medications on the n-3 to n-6 PUFA balance. We here expand 
on this idea, describing biochemical and pathophysiologic mechanisms in support of a 
mediation hypothesis that lowering cholesterol may increase risk of suicidal behavior at least 
in part through effects on PUFAs.
2. Proposed model connecting cholesterol reduction with PUFA status 
and suicidal behavior
To postulate a pathogenic and/or causal relationship between cholesterol, PUFAs and 
suicidal behavior, biological plausibility is needed. As described below and modeled in 
Figure 1, putative mechanisms include alteration of membrane lipid raft structure by the 
proportions of cholesterol and n-3 PUFAs, affecting the functioning of membrane-bound 
proteins including serotonin receptors and transporters, and toll-like receptors. Cholesterol 
lowering also can increase the n-6:n-3 PUFA ratio, thereby promoting inflammation, since 
n-3 PUFAs tend to be anti-inflammatory and n-6 PUFAs tend to be pro-inflammatory 
(reviewed in (Liu et al., 2014)). More indirectly, low n-3 PUFAs disinhibit two inflammatory 
intermediates, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and 
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peroxisome proliferator activated receptors (PPARs). Abnormal monoaminergic 
neurotransmission and the presence of neuroinflammation are two leading theories of 
biological pathways to suicide.
2.1. Effects of PUFAs and cholesterol on lipid rafts
The plasma membrane was conceptualized by Singer & Nicolson (Singer and Nicolson, 
1972) as a fluid mosaic mixture of lipids and proteins. Alternative paradigms have since 
been developed, chief among them the lipid raft concept: a glycerophospholipid bilayer 
containing discrete, spatially and temporally dynamic microdomains (rafts), tightly packed, 
nano-scale membrane assemblies enriched in cholesterol, sphingolipids, and 
glycosylphosphatidylinositol (GPI)-anchored proteins (Hancock, 2006). Lipid rafts interact 
to bring together the components of signaling machinery and influence the trafficking of 
cellular constituents (Ikonen, 2001, Rajamoorthi et al., 2005).
Due to multiple double bonds, the acyl chains of long-chain PUFAs are extremely flexible 
and can rapidly change conformational states (Feller and Gawrisch, 2005), resulting in poor 
packing and higher fluidity, aversive to the tightly-packed, highly ordered cholesterol/
sphingolipid raft domains. In vitro, disruption of lipid rafts is accomplished by reducing 
cholesterol through techniques such as depletion (Sjogren et al., 2006), sequestration 
(Schnitzer et al., 1994), or replacement with sterols that do not serve to form ordered 
domains (Vainio et al., 2006). Studies with in vivo mouse models (Fan et al., 2004, Fan et 
al., 2003), cell cultures (Grimm et al., 2011, Kim et al., 2008), and model membranes 
(Kinnun et al., 2018, Williams et al., 2012) also agree that n-3 PUFAs alter lipid raft 
composition. However, contradictory findings have been reported, as to whether n-3 PUFAs 
promote the formation of lipid rafts and cause increased membrane order, by herding the 
cholesterol and sphingolipids into larger domains (Kim, 2008, Kinnun, 2018); or cause 
decreased membrane order by lowering the levels of cholesterol (Ma et al., 2004) and 
sphingolipids (Fan, 2004, Fan, 2003) within lipid rafts, shifting the cholesterol to non-raft 
domains (Grimm, 2011). One study reports that, in contrast to a more global lowering of 
membrane cholesterol due to pharmacologic depletion, n-3 PUFAs reduce cholesterol only 
in caveolae (Ma, 2004), and notes that studies in T-cells, which lack caveolae, do not exhibit 
decreased cholesterol (Fan, 2004, Fan, 2003). Counterintuitively, given the aversion between 
cholesterol and unsaturated fatty acid chains, several studies in T-cells report that n-3 PUFAs 
incorporate into the lipid rafts (Fan, 2004, Fan, 2003, Stulnig et al., 2001). Thus prediction 
about in vivo clinical effects of cholesterol and n-3 PUFAs on lipid raft functioning is 
necessarily somewhat speculative.
2.1.1. Effects of PUFAs and cholesterol on lipid rafts: serotonergic 
neurotransmission.—Membrane lipid rafts are one arena where PUFA balance and 
cholesterol reduction intersect and may influence suicide risk by affecting functioning of 
membrane proteins such as monoaminergic transporters and receptors. Among 
monoaminergic transporters and receptors that are regulated by lipid rafts, we hypothesize 
that lipid raft alterations would have the greatest impact on suicide risk via effects on 
serotonin (5-hydroxytryptamine, 5-HT) transporters (SERT) and receptors, given the 
associations of the serotonergic pathway with suicidal behavior (reviewed in (Mann, 2003, 
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Oquendo, 2014, van Heeringen and Mann, 2014)). Both SERT (Magnani et al., 2004, 
Samuvel et al., 2005), which regulates synaptic 5-HT concentrations and has effects on the 
5-HT receptors, and the 5-HT receptors themselves, most notably the 5-HT1A (Kalipatnapu 
and Chattopadhyay, 2005, Kobe et al., 2008, Nothdurfter et al., 2011, Renner et al., 2007, 
Sjogren et al., 2008), 5-HT2A (Dreja et al., 2002, Mialet-Perez et al., 2012, Sommer et al., 
2009), 5-HT3A (Eisensamer et al., 2005, Ilegems et al., 2005, Nothdurfter et al., 2010), and 
5-HT7A (Sjogren, 2006, Sjogren and Svenningsson, 2007a, b), localize to lipid rafts.
In vitro studies find that disruption of lipid rafts by cholesterol-interfering agents produces, 
on average, a 50% decrease in the transport rate of the SERT and a concurrent reduction in 
SERT affinity for 5-HT, suggesting that lipid rafts may promote a high-affinity state of 
SERT (Magnani, 2004, Scanlon et al., 2001). Likewise, reduction of cholesterol reduces 
agonist and antagonist binding at the 5-HT1A (Kalipatnapu and Chattopadhyay, 2005, 
Sjogren, 2008) and 5-HT7A (Sjogren, 2006) receptors. Interestingly, co-accumulation of 
certain psychotropic drugs and 5-HT3A receptors in lipid raft fractions is associated with 
effects on serotonin-induced cation currents (Eisensamer, 2005), suggesting possible lipid 
raft-mediated effects of antidepressants and antipsychotics on therapeutic efficacy, including 
reduction of suicide risk.
Direct evidence of a relationship between PUFAs and serotonergic neurotransmission is 
limited to rat models, in which n-3 deficiency induces higher basal and lower stimulated 
levels of serotonin (Kodas et al., 2004) and increased central 5-HT turnover (McNamara et 
al., 2010a), while high n-6 diets cause alterations in 5-HT2A and 5-HT2C receptors and in 5-
HT transporter binding (Dubois et al., 2006).
2.1.2. Effects of PUFAs and cholesterol on lipid rafts: toll-like receptors.—
Another potential factor in suicide risk involving lipid rafts is the balance of opposing effects 
of cholesterol and DHA on the dimerization and recruitment of Toll-like receptors (TLR) 
into lipid rafts. TLRs are pattern recognition receptors that play a key role in recognizing 
pathogens and triggering immune responses by inducing microglial activation and cytokine 
production. TLR also activate nuclear factor kappa light chain enhancer of activated B cells 
(NF-κB), a heterodimeric transcription factor that when activated rapidly migrates into the 
nucleus of the cell and promotes inflammation through effects on target genes controlling 
the expression of multiple cytokines, chemokines, adhesion molecules and vascular cell 
adhesion molecules, and inducible enzymes (Hayden and Ghosh, 2012). Cholesterol and 
lipid rafts are necessary for TLR activation (Sadikot, 2012). DHA, on the other hand, as one 
of its anti-inflammatory actions, inhibits the dimerization of TLR, particularly TLR4, and its 
recruitment into lipid rafts (Wong et al., 2009), and thereby also prevents NF-κB 
translocation into the nucleus (Chen et al., 2017). Lowering of cholesterol could 
theoretically disrupt lipid rafts and reduce TLR function and inflammation, but cholesterol-
lowering effects of reducing DHA can have the opposite effect, reversing the DHA 
inhibition of TLR and thus increasing inflammation. Thus a complex balancing of effects 
remains to be parsed out.
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2.2. PUFA interactions with PPARs
NF-κB is also modulated by the peroxisome proliferator-activated receptors (PPARs) family 
of nuclear transcription factors, for which EPA, DHA and eicosanoids are natural ligands. 
Upon activation by EPA or other ligands, PPARs form heterodimers with retinoid X that 
bind to PPAR-responsive elements in the regulatory region of target genes, reducing the 
expression of proinflammatory molecules. Thus, in addition to inhibition of NF-κB via 
effects on TLR4, n-3 PUFAs downregulate NF-κB through binding to PPARγ (Rao and 
Lokesh, 2017). As cholesterol-lowering reduces both DHA effects on TLR and EPA effects 
on PPARγ, increased inflammation could ensue.
2.3. PUFA balance and inflammation
It has long been known that hormones and neurotransmitters which bind to membrane 
receptors that activate phospholipase A2 release PUFAs from the sn-2 position of membrane 
phospholipids to become substrates for eicosanoid biosynthesis, producing a variety of 
compounds with pro or anti-inflammatory effects. Most of the mediators formed from n-3 
PUFAs have anti-inflammatory effects, while those synthesized n-6 PUFAs are mainly pro-
inflammatory. Very recently, attention also has been focused on anti-inflammatory 
consequences of n-3 PUFA via effects on macrophages and microglia (Fourrier et al., 2017, 
Hopperton et al., 2016, Rombaldova et al., 2017, Shen et al., 2017). Elevation of the n-6:n-3 
PUFA ratio thus causes a shift toward a pro-inflammatory state, which has emerged as a 
potentially important factor in the pathophysiology of suicidal behavior. Pro-inflammatory 
cytokines, particularly IL-6, are associated with suicidal ideation and both nonfatal suicide 
attempts and suicides (reviewed in (Gananca et al., 2016)).
2.4. Effect of cholesterol lowering interventions on PUFA levels
The initial observation of the association between lowering cholesterol serum levels and 
suicide came from intervention studies (Muldoon, 1990). However, those studies did not 
measure effects of the interventions on PUFA serum levels. As described below, there is 
some evidence that cholesterol-lowering interventions, besides modifying cholesterol, affect 
PUFA serum levels, which thus could perhaps be a mediator of the cholesterol-suicide 
connection.
2.4.1. Effect of fibrates on PUFAs—Fibrates are synthetic ligands for PPARα 
receptors, and it is through binding to these nuclear receptors that they act to alter lipid 
levels. Fibrates primarily reduce triglycerides, have a modest effect on HDL-C levels, and, 
depending upon the baseline triglyceride levels, may decrease LDL-C levels (in patients 
without baseline elevation in triglyceride levels) or may substantially increase LDL-C levels 
(in patients with very high baseline triglyceride levels). (Goldenberg et al., 2008)
Information regarding the effect of fibrates on PUFAs is conflicting, and it seems that the 
action varies with the type of fibrate. In animal models, bezafibrate, and to a lesser extent 
gemfibrozil, increase monounsaturated fatty acids (palmitoleic and oleic acids) and decrease 
PUFAs (mainly linoleic acid has been studied) in microsomal phospholipids (Vazquez et al., 
1995). In humans, gemfibrozil produces major modifications in fatty acid composition, 
decreasing saturated fatty acids and increasing n-6 PUFA (Nyalala et al., 2008). A 
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conflicting finding in an animal model (rat heart) is that clofibrate treatment reduces n-6 
PUFAs (linoleic acid and arachidonic acid) and increases n-3 PUFA (DHA) and increases 
the unsaturation extent of myocardial fatty acids (Tian et al., 2006). Taken together, these 
results suggest that fibrates alter PUFAs serum levels, apparently diminishing n-3 PUFAs. 
However, this effect is not equivalent for all drugs.
2.4.2. Effect of statins on PUFAs—Statins were originally believed to be effective in 
treating cardiovascular illness by inhibiting the synthesis of mevalonate, acting on HMG-
CoA reductase, and thereby reducing the serum levels of LDL and increasing HDL (Stancu 
and Sima, 2001). However, statins have pleiotropic biochemical effects beyond the 
inhibition of cholesterol synthesis and some of these effects modify PUFA levels, altering 
the balance of n-3 to n-6 PUFAs, apparently by affecting desaturation and elongation (Rise 
et al., 2001).
In cultured monocytic cells, simvastatin activates the formation of AA from LA, mainly 
acting at the delta 5 desaturation steps, and increases the mRNA levels of delta 5 desaturase 
(Rise et al., 2002). In patients with dyslipidemia, rosuvastatin and pitavastatin decrease 
serum DHA and increase the AA/DHA ratio (Nozue and Michishita, 2015); similarly, 
pravastatin and simvastatin treatment increase the AA/EPA ratio (Harris et al., 2004, 
Nakamura et al., 1998) and tend to increase the AA/DHA ratio (Harris, 2004).
Taken together, this information suggests that statins affect PUFA synthesis, particularly 
increasing serum concentration of AA or the concentration of AA relative to n-3 PUFAs 
(DHA and EPA), although as for fibrates, individual statin drugs may have differing effects.
2.4.3. Comparisons of fibrate and statin effects on PUFAs—Several studies have 
simultaneously assessed the effects of fibrates and statins. In one study of plasma lipids of 
hyperlipidemic patients, elevation of AA occurred in those treated with statins but not those 
treated with fibrates; AA elevation was associated with concomitant selective escalation of 
product/precursor ratios for delta 5 desaturation in hypercholesterolemic patients (Rise, 
2001). The opposite result was seen in another study which compared the magnitude of 
effects of atorvastatin, simvastatin and gemfibrozil (Nyalala, 2008), on fatty acid 
composition in human plasma and red blood cell membranes; they found that n-6 PUFA 
levels were increased with both treatments, but the effects of gemfibrozil were significant 
while the effects of statins were not. Finally, a study comparing patients treated with 
fenofibrate vs. simvastatin for 3 months found significant increases in both groups for n-6 
PUFAs, including AA and other intermediate n-6 species, and a concomitant decrease in the 
n-6 precursor, LA, but observed a decrease in two major n-3 PUFAs (ALA and DHA) in 
fibrates only (de Lorgeril, 2005). At this time, there is no resolution of these contradictory 
findings. Differentially stronger effects of fibrates on PUFA balance could, however, pertain 
to why the most recent meta-analysis (Muldoon, 2001) found a trend (p=0.06) in increased 
risk of suicide/violent death/accidents with respect to fibrates but no increase with respect to 
statins.
2.4.4. Effect of proprotein convertase subtilisin-kexin type 9 serine protease 
(PSCK9) inhibitors—New, highly effective cholesterol lowering drugs, PSCK9 inhibitors, 
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have not been associated with suicidal behavior, according to a meta-analysis of 13,083 
patients in 17 clinical trials (Lipinski et al., 2016); however, neurocognitive side effects 
(amnesia, alterations in memory and confusional state) were reported. Taking into account 
that there are still few studies published and with short-term follow-ups, potential effects of 
PSCK9 inhibitors on suicidal behavior should not be ruled out. In a cardiovascular context, 
effects of dietary n-3 PUFAs may be mediated by direct effects of DHA on PCSK9. 
(Graversen et al., 2016, Rodriguez-Perez et al., 2016, Yu et al., 2017)
2.4.5. Effect of cholesterol-lowering diets on PUFA levels—In the meta-analyses 
of Muldoon et al. (Muldoon, 1990, Muldoon, 2001), subjects undergoing dietary 
interventions (Z-score=1.77, p=0.08 (Muldoon, 1990)) or dietary interventions lumped with 
non-statin treatment (OR=1.32; CI=1.32-0.98; p=0.06 (Muldoon, 2001)) showed a trend 
toward increased death from non-illness mortality. Details of the dietary interventions were 
not available.
3. Discussion
We have expanded upon the previous work of Hibbeln and Salem, who postulated that, 
“fatty acids may be a critical variable which links cholesterol lowering therapies to suicide 
or depression,” (Hibbeln and Salem, 1996). Our theoretical model explicates several 
possible pathways whereby cholesterol-lowering treatments can affect PUFAs and lipid 
rafts, leading to alterations in serotonergic neurotransmission and/or inflammation and 
thereby increase suicide risk.
Complexities in the proposed model center around how effects of cholesterol lowering and 
changes in PUFA balance affect lipid rafts, which have some of the qualities of a “black 
box”. We know that aversive relationships between highly unsaturated fatty acids and large 
cholesterol and sphingolipid molecules have biophysical effects on lipid raft structure with 
functional consequences. However, lipid rafts pose extreme technical challenges for clinical 
study, as rafts are dynamic systems that are nanoscalar, both temporally and molecularly. 
Thus to date, current knowledge relies on studies in model membranes, cell culture, and 
some in vivo rodent studies.
Another complexity is that although statins have been shown to decrease cholesterol and 
increase n-6 PUFA blood levels with respect to n-3 levels, a meta-analysis performed in 
2001 found that in contrast to fibrates and diet, statins showed not only no significant 
increase in deaths by accidents, violence, and suicide, but rather a tendency to reduce non-
illness mortality (Muldoon, 2001). In concordance with our explanatory model, this may be 
due to a greater impact of fibrates compared with statins on PUFA status (de Lorgeril, 2005, 
Nyalala, 2008). Additionally, statin mechanisms of action other than lipid reduction have 
been recognized (Tousoulis et al., 2014), including anti-inflammatory properties. Meta-
analyses suggest that statins’ benefits for atherosclerosis are primarily associated with their 
anti-inflammatory actions (An et al., 2017, Li et al., 2018), particularly in the case of 
lipophilic statins (Bonsu et al., 2015), which also comports with the premise in our model 
that lipid effects on suicide risk may relate to their effects on inflammatory state. Thus, 
statins’ anti-inflammatory properties may actually mitigate suicide risk.
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Another relevant question is whether statins have any effects on aggression, which may be a 
psychiatric mediator or moderator of suicidal behavior. One randomized clinical trial 
(Golomb et al., 2015) has addressed this question, finding age and sex effects of statin 
treatment: aggression was decreased in men, particularly men with low baseline aggression, 
after outliers were removed; these outliers included men in whom statins induced markedly 
increased aggression, and this was found to be associated with statin-induced side effect of 
sleep problems. Moreover, aggression was increased in postmenopausal women. The same 
research group also reported on a case series of 12 patients who took statins and self-referred 
for assessment of subsequent mood or behavior changes including irritability, depressed 
mood, and suicidal ideation, suicide attempts and suicide completion (Cham et al., 2016). 
From a precision medicine standpoint, these findings suggest that although in the aggregate 
statins tend to decrease suicide risk, certain individuals may have a biological or behavioral 
phenotype that would confer vulnerability to statin-induced aggression, depression and 
suicide risk.
We have described mechanisms through which cholesterol-lowering drugs may increase the 
proportion of n-6 PUFAs. Dietary interventions also showed a trend toward increased 
suicide mortality (Muldoon, 1990, Muldoon, 2001). How does this relate to the hypothesis 
that cholesterol relationships to suicide risk are confounded by the underlying PUFA 
balance? The specifics of the dietary interventions included in these meta-analyses are not 
readily available for examination. However, U.S. dietary guidelines (Office of Disease 
Prevention and Healthy Promotion, 2017) on lipid consumption for 1990 stated, “Choose 
liquid vegetable oils most often because they are lower in saturated fat” and similarly for 
2000, “Choose vegetable oils rather than solid fats (meat and dairy fats, shortening).” 
Although the Mediterranean diet had been proposed previously (Keys and Keys, 1975), 
possible benefits of using olive oil and n-3-rich oils were not widely recognized during that 
time period. Assuming that dietary interventions for improved heart health adhered to the 
nutritional wisdom of the time, then it is likely that study participants were instructed to 
choose vegetable oils over animal fats. Analysis of n-3 and n-6 PUFA concentrations in a 
sampling of 14 vegetable oils (olive oil and canola oil were not included) found the average 
amount of n-6 PUFAs to be 43.4 ± 24.7% of total fatty acid methyl esters while n-3 PUFAs 
made up only 0.47 ± 0.53% (Orsavova et al., 2015). Thus, comporting with our model, 
increasing intake of vegetable oils would be expected to have reduced saturated fats but 
increased intake of n-6 PUFAs.
Like any theoretical schema, our proposed model is an oversimplification. As yet 
understudied is the extent to which the two pathways we have identified, serotonergic 
neurotransmission and inflammation, may be related and create a final common pathway to 
suicide risk. Along these lines, there are reports that serotonin reuptake inhibitors inhibit 
activation of microglia (Su et al., 2015) and that an abnormal astrocyte-microglia balance is 
associated with impaired serotonergic functioning (Müller and Schwarz, 2007).
To better understand treatment effects of PUFAs, future studies should assess diet, taking 
into account not just concentrations of PUFAs but also percentage composition and the 
relative effects across the lipidome on different lipid classes (phospholipids, cholesteryl 
esters, unesterified fraction). Additional important factors to be studied include lipid-
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associated genetic variants and epigenetic marks that modulate the effects of lipid status on 
suicide risk.
4.1. Limitations
In reviewing the literature pertinent to cholesterol, PUFAs and suicide risk, we are hampered 
by the lack of a) clinical trials with suicidal behavior as outcome measures and b) studies 
that fully characterize the lipidome. Therefore, although evidence supports each step in our 
hypothesized model (Fig 1), and the model possesses face validity, in order to establish 
mechanisms of action as postulated in our model, mediation analyses would need to be 
undertaken, which require large sample sizes.
4.2. Conclusions
Based on a survey of relevant scientific literature, we propose links between low cholesterol, 
elevated n-6 to n-3 PUFAs, lower 5-HT neurotransmission, inflammation, and suicide risk. 
Effects of cholesterol-PUFA balance on lipid rafts are a mechanistic linchpin deserving of 
additional study in this regard. If our model is correct, the use of cholesterol-lowering 
treatments has implications for personalized medicine as well as an impact on public health. 
There could be preventative value, with respect to suicide, in administering n-3 PUFA 
supplements to cardiac patients for whom lower cholesterol is medically important and who 
have or develop psychiatric vulnerabilities.
Abbreviations:
DHA docosahexaenoic acid
EPA eicosapentaenoic acid
PPARs peroxisome proliferator-activated receptors
TLR Toll-like receptor
NF-KB nuclear factor kappa-light-chain-enhancer of activated B cells
5-HT 5-hydroxytryptamine (serotonin)
PUFAs polyunsaturated fatty acids.
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Figure 1. Theoretical schematic of pathways through which an elevated n-6 to n-3 PUFA ratio 
could affect suicide risk.
Treatment with (1) diet, (2) fibrates and (3) statins that lower (4) cholesterol can cause (5) 
disruption of lipid rafts with functional consequences, due to lipid raft regulation of 
serotonin transporters and receptors, resulting in (6) decreased serotonergic 
neurotransmission, which has been shown to increase (12) suicide risk. (1) Diets replacing 
saturated fats with polyunsaturated oils high in n-6 PUFAs and (2) fibrates also can cause an 
increase in (7) the ratio of n-6 to n-3 PUFAs. This is, effectively, a lowering of n-3 that also 
is expected to contribute to (5) destabilization of lipid rafts, although directional effects of 
PUFAs on lipid rafts are complex and incompletely understood. More clearly, a higher n-6 to 
n-3 PUFA ratio directly promotes (10) inflammation, which is associated with (12) suicide 
risk. Also, lower n-3 PUFAs can indirectly result in increased inflammation by lowering 
DHA-mediated inhibition of (8) TLR dimerization and activation, resulting in downstream 
increased activation of (9) NF-KB, a (10) pro-inflammatory molecule. Either (1) decreased 
n-3 intake or (2) fibrate competition with EPA can reduce EPA binding to PPARs. Since (11) 
the EPA*PPARs complex acts as a brake on (9) NF-KB, interference with the EPA*PPARs 
complex via both mechanisms also contributes to activation (disinhibition) of (9) NF-KB. 
Counter to these pro-inflammatory forces, (5) decreased lipid raft functioning could 
decrease (8) TLR recruitment into lipid rafts and activation; and (3) statins may have lesser 
effects on (7) the n-6 to n-3 ratio and they also exert pleiotropic (10) anti-inflammatory 
effects that may mitigate (12) suicide risk. See text for all references substantiating these 
relationships.
Daray et al. Page 19
J Psychiatr Res. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
